In these circumstances, HRT should be prescribed to the woman only in consultation with the breast surgeon or oncologist. Literally hundreds of clinical trials have provided evidence that systemic HT effectively supports conditions such as hot flashes, vaginal dryness, night sweats, and bone loss. These benefits can lead to improved sleep, intercourse, and quality of life. Because of this increased risk of cancer, women who have gone through menopause and still have a uterus are given progestin along with estrogen. Studies have shown that EFA does not increase the risk of endometrial cancer.
More than 5,000 women in the ET group took a daily dose of estrogen in the form of conjugated horse estrogen for an average of about 6 years. The researchers then followed them for several years to look for more effects of the hormone. Different types of studies can be used to investigate the cancer risk of hormone therapy during menopause. For those with cancer who have undergone treatments that affect their estrogen levels, BHRT has been shown to be effective in improving their overall well-being and quality of life. In one study, people with cancer who underwent BHRT found relief from treatment-related symptoms such as migraines, incontinence, low libido, and insomnia. The study also found that their breast cancer recurrence rate was no higher than average.
For women who have had a hysterectomy, progestin does not need to be part of hormone therapy because there is no risk of endometrial cancer. Adding a progestin increases the risk of breast Hormone Replacement Therapy Near Me cancer, making it a better choice for women without a uterus. Women who took estrogen plus progestin were more likely to be diagnosed with breast cancer than women who took placebo.
Other studies have found a link between systemic pure estrogen HRT and an increased risk of ovarian cancer. The re-analysis of GHI data by age cohort showed that the risks of breast cancer, stroke and heart disease did not increase in the fifth decade, but increased in the sixth and seventh decades. The risk of breast cancer was evident in women who were exposed to high blood pressure before entering the GHI study after a washout phase, but not in those who had never received HT. HRT first became available in the 1940s, but became more widespread in the 1960s, leading to a revolution in menopause management. It is advisable for women with a history of breast cancer to avoid HRT unless other treatments are ineffective and their quality of life becomes unbearable due to menopausal symptoms.
There is no one way to ensure the best possible quality of life around menopause and beyond. Every woman is unique and needs to weigh her discomfort against her fear of treatment. Risk is defined as the possibility or possibility of harm; It does not indicate that damage will occur. Overall, the risks of high blood pressure in younger women are lower than originally in all women aged 50 to 70 combined.
Studies from the Women’s Health Initiative also found no increased risk of breast cancer in women who use systemic HRT with estrogen alone. Years ago, before the link between HRT use and breast cancer risk became known, many women took HRT for years to relieve menopausal symptoms and prevent bone loss. After 2002, when research linked HRT and breast cancer risk, the number of women taking HRT dropped dramatically.
Hormone therapy is one of the state-approved treatments for relieving menopausal symptoms. These symptoms, caused by lower levels of estrogen during menopause, include hot flashes, sleep disturbances, and vaginal dryness. Today, doctors prescribe much lower doses for much shorter periods of time (3-5 years) than before 2002. Your age, family history, personal medical history, and severity of your menopausal symptoms are factors that can influence your decision to pursue hormone therapy. Talk to your healthcare provider about the benefits and risks of HTN, the different forms of HTN, and other alternative options. This analysis found that women who took estrogen after menopause had an increased risk of developing ovarian cancer.